Filed under: Health Sciences Global Business Unit, oracle, Oracle Health Sciences Global Business Unit | Tagged: clinical research, Drug Development, health sciences global business unit, Lifescience, lifescience cloud, Oracle health sciences global business unit | Leave a comment »
How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine
Single patient Clinical Trial are not new idea, FDA did not focus since such trial canot prove the efficacy and safety of medicine over a large pool of patient with sufficient data. But I was forced to re-think after reading the article http://www.technologyreview.in/biomedicine/12537/ why cant we use the the concept mentioned in to overcome the ethical and other challenges in current mode of trials.
So I decided to ask the question to the linkedin audience http://www.linkedin.com/answers/technology/biotech/TCH_BIO/667022-9262868?browseIdx=0&sik=1272969161323&goback=.amq
Filed under: clinical research, Clinical Trial, Patient Safety, personalized medicine, pharmacovigilance | Tagged: health sciences global business unit, Oracle health sciences global business unit | 1 Comment »
GE Health Care is rolling out a new, cloud-based platform that makes it easier for physicians with small practices to maintain and keep track of the electronic medical records of their patients. The new SAAS offering is part of GE’s Centricity offering.
Introducing Centricity Advance
Colonnades Family Medicine is running on Centricity Advance, a web-based EMR solution launched today by GE Healthcare and specifically designed for the smaller physician practice.
Unlike most clinical and financial management solutions, Centricity Advance is a web-based service that costs less than a standard client-server software deployment and is maintained and supported with little or no strain on the healthcare provider’s resources, freeing up more time for patient care.
Ideal as a Web-Based Service
The fact that Centricity Advance was designed from the ground up as a web service is significant. Instead of simply providing web-based gateway into a standard EMR application, the Centricity Advance is created with anywhere/anytime access in mind, resulting in an intuitive and efficient interface without sacrificing functionality. Since system management is centralized as part of the Centricity Advance service, small practices don’t have to worry about data protection, updates, equipment failures and other typically stressful responsibilities of user-driven IT management.
Another key feature of Centricity Advance is the Patient Self-Service Portal, which connects patients to their care. By using their own secure password to log in, patients can communicate privately with their doctor and view their own information such as statements, prescriptions and lab results. Patients can also request and confirm appointments, request prescription refills and get automatic reminders for immunizations and lab tests.
Filed under: cloud computing, SaaS | Tagged: cloud computing, EHR, EMR, health sciences global business unit, healthcare IT, Oracle health sciences global business unit, SaaS, Software-as-a-Service | 4 Comments »
Grid computing projects supported by Big Blue announced significant progress in looking for new potential drugs in cancer treatment
Filed under: cloud computing, collaborative research, open source, SaaS, web2.0 | Tagged: cloud computing, grid computing, health sciences global business unit, lifescience cloud, open source, Oracle health sciences global business unit, SaaS | Leave a comment »
The Australian Research Collaboration Service (ARCS) www.arcs.org.au has launched its Computer Cloud scheme, a $22 million project funded by the government’s National Collaborative Research Infrastructure Strategy.
More details check http://www.arcs.org.au/index.php/services/cloud-computing
Bob Correll, the chief information officer for the Department of Immigration and Citizenship, said his agency is also looking into using cloud computing for its electronic visa system
Filed under: clinical software, cloud computing, lifescience, Online Data sharing, open source, SaaS | Tagged: health sciences global business unit, Oracle health sciences global business unit | Leave a comment »
GlaxoSmithKline has teamed up with MedTrust Online, provider of specialist data and technology to oncologists, to launch CancerTrialsApp, described as “the first free geo locating cancer clinical trials application” for the Apple iPhone and iPad.
The application enables cancer doctors to find and share with their patients information about experimental therapies in clinical trials
Filed under: clinical informatics, clinical research, clinical software, Clinical Trial, Visual Clinica | Tagged: health sciences global business unit, Oracle health sciences global business unit | Leave a comment »
F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent
Plans by FDA to Adopt stricter standards for Bioequivalence, Bioavailability for generic drugs could sound trouble for Indian Generic Manufactures. Already most of the smaller companies are finding it difficult to get FDA approval letters. QSR Draft Guidance An industry working group has urged the FDA to consider adopting its guidance to outline quality system requirements (QSR) for bioequivalence and bioavailability testing during drug clinical trials.
There was a recent report in NY times that mentioned about several thousand patients receiving nitroglycerin tablets that were not approved by FDA http://www.nytimes.com/2010/03/27/business/27nitro.html
FDA recently evaluated 2070 human studies conducted between 1996 and 2007. These studies compared the absorption of brand name and generic drugs into a person’s body. These studies were submitted to FDA to support approval of generics. The average difference in absorption into the body between the generic and the brand name was only 2.3%. Some generics were absorbed slightly more, some slightly less. This amount of difference would be expected and acceptable, whether for one batch of brand name drug tested against another batch of the same brand, or for a generic tested against a brand name. In fact, there have been studies in which branded drugs were compared with themselves, as well as with a generic. As a rule, the difference for the generic-to-brand comparison was about the same as the brandto- brand comparison” (www.fda.gov/ Drugs/ResourcesForYou/Consumers/ BuyingUsingMedicineSafely/Under standingGenericDrugs/ucm167991. htm)
Fore more updates attend the event below